 2. Previous or concomitant malignancy - EXCEPTIONS: Patients with curatively treated carcinoma in situ of the cervix, basal cell of the skin, transitional cell carcinoma of the bladder, or early stage cancers at non-overlapping sites with no evidence of disease for 3 years. 